| Norfloxacin EP Impurity D |
诺氟沙星EP杂质D |
75001-82-0 |
| Parecoxib Sodium Impurity 14 |
间位帕瑞昔布 |
1709956-89-7 |
| Erlotinib iMpurity B |
厄洛替尼杂质B |
183321-83-7 |
| 1-(4-Hydroxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide |
1-(4-羟基苯基)-7-氧代-6-[4-(2-氧代哌啶-1-基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-C]吡啶-3-甲酰胺 |
503612-76-8 |
| Sorafenib related compound 10 |
索拉非尼相关化合物A |
1012058-78-4 |
| Alogliptin Impurity B |
苯甲酸阿格列汀杂质F |
865758-98-1 |
| Rosuvastatin IMpurity SodiuM Salt (5-Oxo Rosuvastatin SodiuM Salt) |
Rosuvastatin IMpurity SodiuM Salt (5-Oxo Rosuvastatin SodiuM Salt) |
1422619-13-3 |
| 2-PyrazinecarboxaMide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-Methylbutyl]aMino]-2-oxo-1-(phenylMethyl)ethyl]- |
硼替佐米杂质K |
886979-78-8 |
| Loxoprofen Ring-opening IMpurity |
氯索洛芬开环杂质 |
1091621-61-2 |
| 4-(4-(3-(4-chloro-3-(trifluoroMethyl)phenyl)ureido)-3-fluorophenoxy)-2-(MethylcarbaMoyl)pyridine 1-oxide |
瑞戈非尼杂质 13 |
835621-11-9 |
| Etoricoxib Impurity 11 |
依托考昔去甲基杂质 |
202409-31-2 |
| Acyclovir N-Methylene Dimer |
阿昔洛韦杂质K |
1797131-64-6 |
| APOHYOSCINE |
东茛菪碱 |
535-26-2 |
| Paclitaxel IMpurity F |
紫杉醇杂质F |
153083-53-5 |
| GSK2837808A |
1445879-21-9 |
1445879-21-9 |
| carbamic acid, n-[(1r,2r,5s)-5-[(dimethylamino)carbonyl]-2-hydroxycyclohexyl]-, 1,1-dimethylethyl ester |
依度沙班杂质O |
929693-30-1 |
| Levofloxacin Related CoMpound E |
左氧氟沙星相关物质E |
1346603-62-0 |
| Dabigatran Impurity p |
达比加群酯杂质F |
1408238-37-8 |
| Dabigatran etexilate Impurity R |
达比加群乙二酸杂质R |
1610758-20-7 |
| 2-(DiethylaMino)-N-(2,4-diMethylphenyl)acetaMide Hydrochloride |
2-(二乙氨基)-N-(2,4-二甲基苯基)乙酰胺盐酸盐 |
17289-54-2 |
QQ
微信
